Corrupt Agencies

THIS POST IS TO BRING AWARENESS TO GOVERNMENTAL AGENCY CORRUPTION

CREDIT GOES TO representus @ YOUTUBE

HOW BRIBERY (FUNDING) AFFECTS AGENCY DECISIONS

ACCORDING TO COPILOT:

in the United States, a significant number of politicians have financial interests in pharmaceutical companies. Here are some key points:

1. Congress:

   • Two-thirds of Congress (72 senators and 302 members of the House of Representatives) received campaign contributions from the pharmaceutical industry ahead of the 2020 election.

   • Pfizer and Amgen were major contributors, with their political action committees (PACs) donating to nearly half of lawmakers on Capitol Hill.

   • Overall, the pharmaceutical sector donated $14 million during the election cycle.

2. State Legislators:

   • Over the last two years, (2022-2024) at least 2,467 state legislators (over one-third of all state lawmakers nationwide) used pharmaceutical industry funds to support their campaigns.

3. Investments:

   • About 30% of senators and 20% of representatives held assets in biomedical and health-care companies or specialty funds investing in those industries during 2014.

   • Pfizer is a popular stock among lawmakers, with several holding significant investments in the company.

In summary, while exact percentages may vary, it’s clear that many politicians have financial ties to pharmaceutical companies. These relationships can influence policy decisions and raise ethical questions. 

While I couldn’t find an exact percentage of FDA employees or directors who have moved to biopharmaceutical companies, the “revolving door” phenomenon is well-documented. This term describes the movement of personnel between roles as regulators in the public sector and as employees or lobbyists in the private sector.

Here are a few notable examples of FDA officials who have transitioned to the biopharmaceutical industry:

1. Scott Gottlieb - Former FDA Commissioner, joined the board of Pfizer.

1. Margaret Hamburg - Former FDA Commissioner, joined the board of Alnylam Pharmaceuticals.

1. Robert Califf - Former FDA Commissioner, worked with Verily Life Sciences and Google Health.

1. Amy Abernethy - Former Principal Deputy Commissioner, joined Verily Life Sciences.

1. Joshua Sharfstein - Former Principal Deputy Commissioner, joined the board of the Commonwealth Fund.

2. Janet Woodcock - Former Acting FDA Commissioner, joined the board of the Reagan-Udall Foundation for the FDA.

3. Stephen Hahn - Former FDA Commissioner, joined Flagship Pioneering.

4. Peter Marks - Director of the Center for Biologics Evaluation and Research, joined the board of the International Society for Cell & Gene Therapy.

5. Rachel Sherman - Former Principal Deputy Commissioner, joined the board of the Reagan-Udall Foundation for the FDA.

6. John Jenkins - Former Director of the Office of New Drugs, joined Greenleaf Health.

This movement can raise concerns about potential conflicts of interest and regulatory capture, where regulatory decisions might be influenced by future job prospects in the industry.